^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    garetatug rezetecan (SHR-A1904)

    i
    Other names: SHR-A1904, SHRA1904, SHR A1904, SHR-1904
    Associations

    News

    Trials
    Company:
    EMD Serono, Jiangsu Hengrui Pharma
    Drug class:
    Topoisomerase I inhibitor, CLDN18.2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    1m
    A Multicenter, Open-Label Phase II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of SHR2554 Tablets in Combination with Other Antitumor Therapies in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma (ChiCTR2500110933)
    P2, N=366, Recruiting, Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
    |
    PD-L1 expression • HER-2 expression
    |
    trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • AiRuiLi (adebrelimab) • garetatug rezetecan (SHR-A1904)
    1m
    Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules. (PubMed, Front Mol Med)
    Enfortumab vedotin is an NECTIN4-targeting antibody-drug conjugate that is approved for the treatment of urothelial cancer, whereas other ADCs or derivatives that target NECTIN4, such as bulumtatug fuvedotin, SHR-A2102 and zelenectide pevedotin, are being studied in randomized phase III clinical trials. In contrast, arcotatug tavatecan, garetatug rezetecan, sonesitatug vedotin and tecotabart vedotin are anti-CLDN18.2 ADCs in phase III clinical trials for the treatment of CLDN18.2-positive gastric or gastroesophageal junction adenocarcinomas, and raludotatug deruxtecan is an anti-CDH6 ADC in a phase II/III clinical trial for the treatment of platinum-resistant ovarian cancer. ADCs that target cell-cell adhesion molecules are a rapidly emerging class of cancer therapeutics, and bispecific ADCs and longitudinal companion diagnostics are emerging to further improve the clinical benefits of conventional ADCs.
    Review • Journal
    |
    CLDN18 (Claudin 18) • CLDN6 (Claudin 6) • CDH6 (Cadherin 6) • CDH17 (Cadherin 17)
    |
    CLDN18.2 positive
    |
    Padcev (enfortumab vedotin-ejfv) • sonesitatug vedotin (AZD0901) • tecotabart vedotin (LM-302) • zelenectide pevedotin (BT8009) • SHR-A2102 • arcotatug tavatecan (IBI-343) • bulumtatug fuvedotin (9MW2821) • garetatug rezetecan (SHR-A1904) • raludotatug deruxtecan (DS-6000)
    2ms
    A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    trastuzumab rezetecan (SHR-A1811) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • garetatug rezetecan (SHR-A1904)
    3ms
    Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=351, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • garetatug rezetecan (SHR-A1904)
    4ms
    A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P2 trial
    |
    trastuzumab rezetecan (SHR-A1811) • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • garetatug rezetecan (SHR-A1904)
    4ms
    Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=351, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    trastuzumab rezetecan (SHR-A1811) • retlirafusp alfa (SHR-1701) • zeprumetostat (SHR-2554) • garetatug rezetecan (SHR-A1904)
    5ms
    The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. (PubMed, Nat Med)
    In conclusion, SHR-A1904 demonstrated a manageable safety profile and encouraging anti-tumor activity in patients with CLDN18.2-positive G/GEJ cancer, warranting further investigation. ClinicalTrials.gov identifier: NCT04877717 .
    P1 data • Journal
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 positive
    |
    garetatug rezetecan (SHR-A1904)
    9ms
    SHR-A1904-I-101: A Study of SHR-A1904 in Patients With Advanced Solid Cancer (clinicaltrials.gov)
    P1, N=107, Active, not recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jan 2024 --> Dec 2025 | Trial primary completion date: Oct 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    garetatug rezetecan (SHR-A1904)
    9ms
    Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping (clinicaltrials.gov)
    P2, N=140, Not yet recruiting, China Medical University, China
    New P2 trial
    |
    Herceptin (trastuzumab) • AiTan (rivoceranib) • capecitabine • oxaliplatin • trastuzumab rezetecan (SHR-A1811) • Vyloy (zolbetuximab-clzb) • Teysuno (gimeracil/oteracil/tegafur) • retlirafusp alfa (SHR-1701) • AiRuiLi (adebrelimab) • garetatug rezetecan (SHR-A1904)
    12ms
    SHR-A1904-302: SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=524, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    paclitaxel • docetaxel • irinotecan • garetatug rezetecan (SHR-A1904)
    1year
    SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=524, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P3 trial • Metastases
    |
    paclitaxel • docetaxel • irinotecan • garetatug rezetecan (SHR-A1904)
    over1year
    Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Fudan University
    New P2 trial • Metastases
    |
    trastuzumab rezetecan (SHR-A1811) • SHR-A2102 • HRS-4642 • garetatug rezetecan (SHR-A1904)